1. Introduction: Defining and Classifying Chronic Kidney Disease
Chronic Kidney Disease (CKD) represents a spectrum of pathophysiologic processes associated with abnormal kidney function and a progressive decline in glomerular filtration rate (GFR) 1. The formal definition of CKD, as established by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, is the presence of kidney damage or a GFR of less than 60 mL/min/1.73 m² for three or more months, regardless of the underlying cause 2. Evidence of kidney damage can manifest as abnormalities in blood or urine tests, structural abnormalities observed in imaging studies, or pathologic findings from a kidney biopsy 2.
The KDIGO 2024 guidelines have refined the classification of CKD to better predict prognosis and guide management. This classification system is based on three key pillars: Cause, GFR category, and Albuminuria category (CGA). This framework provides a comprehensive assessment of a patient’s CKD status and risk of progression.
GFR Categories
The GFR categories, ranging from G1 to G5, provide a quantitative measure of kidney function. These categories are essential for staging the severity of CKD and for making decisions about drug dosing, monitoring, and referral to a nephrologist.
| Category | GFR (mL/min/1.73 m²) | Description |
|---|---|---|
| G1 | ≥90 | Normal or high GFR, with other evidence of kidney disease |
| G2 | 60-89 | Mildly decreased GFR |
| G3a | 45-59 | Mildly to moderately decreased GFR |
| G3b | 30-44 | Moderately to severely decreased GFR |
| G4 | 15-29 | Severely decreased GFR |
| G5 | <15 or on dialysis | Kidney failure |
Albuminuria Categories
Albuminuria is a key marker of kidney damage and a powerful predictor of CKD progression and cardiovascular events. The KDIGO guidelines categorize albuminuria into three stages based on the albumin-to-creatinine ratio (ACR) in a spot urine sample.
| Category | ACR (mg/g) | ACR (mg/mmol) | Description |
|---|---|---|---|
| A1 | <30 | <3.4 | Normal to mildly increased |
| A2 | 30-299 | 3.4-34 | Moderately increased |
| A3 | ≥300 | ≥34 | Severely increased |
The combination of GFR and albuminuria categories provides a powerful tool for risk stratification, allowing clinicians to identify patients at the highest risk for adverse outcomes and to tailor management strategies accordingly.
2. Epidemiology and Natural History: A Global Perspective
Chronic Kidney Disease has emerged as a major global health problem, with a prevalence of 10-14% in the general population 3. The burden of CKD is substantial, contributing to increased morbidity, mortality, and healthcare costs worldwide. In 2012, CKD was responsible for approximately 1% of global disability-adjusted life-years (DALYs), and in the United States alone, an estimated 26 million people were affected by the disease in 2016 3 4.
The natural history of CKD is highly variable and depends on the underlying etiology, the presence of comorbidities, and the effectiveness of management strategies. A distinction can be made between community-acquired CKD and CKD in patients referred to nephrology clinics.
Community-acquired CKD is often seen in older individuals with a long history of cardiovascular risk factors such as hypertension and diabetes. In this population, the decline in GFR is typically slow, with an average rate of 0.75-1 mL/min/year after the age of 40-50 5. Cardiovascular events are the leading cause of mortality in this group, with a smaller proportion of patients progressing to end-stage renal disease (ESRD) 5.
In contrast, CKD in patients referred to nephrology clinics often affects a younger demographic and is characterized by more aggressive disease. These patients have a higher rate of GFR decline and a greater likelihood of progressing to ESRD, necessitating renal replacement therapy 5.
Several factors have been identified that influence the progression of CKD. Non-modifiable risk factors include age, gender, race, and genetic predisposition. Modifiable risk factors, which are the primary targets of therapeutic interventions, include hypertension, proteinuria, hyperglycemia, and lifestyle factors such as smoking and obesity 6.
3. Etiology and Pathophysiology: Unraveling the Mechanisms of Kidney Damage
The causes of CKD are diverse, but a few common etiologies account for the majority of cases. The leading causes of ESRD are:
•Diabetes Mellitus (Type 1 and 2): Diabetic nephropathy is the most common cause of CKD and ESRD, accounting for 30-50% of cases 3.
•Hypertension: Hypertensive nephrosclerosis is the second leading cause, responsible for approximately 27% of ESRD cases 3.
•Glomerulonephritis: Primary and secondary glomerulonephritides are the third most common cause, contributing to about 10% of ESRD cases 3.
•Other causes: These include polycystic kidney disease, chronic tubulointerstitial nephritis, and obstructive uropathy.
The pathophysiology of CKD progression is complex and involves a final common pathway of glomerulosclerosis and tubulointerstitial fibrosis, regardless of the initial insult. The intact nephron hypothesis posits that as nephrons are lost, the remaining nephrons undergo compensatory hyperfiltration to maintain overall kidney function. This adaptive response, however, becomes maladaptive over time, leading to increased glomerular pressure, shear stress, and ultimately, sclerosis of the remaining glomeruli 7.
Several key molecular pathways contribute to the progression of CKD:
•Renin-Angiotensin-Aldosterone System (RAAS) Activation: Angiotensin II, the primary effector of the RAAS, promotes vasoconstriction, inflammation, and fibrosis, leading to progressive kidney damage 8.
•Inflammation and Fibrosis: Chronic inflammation, mediated by cytokines and immune cells, and the subsequent activation of fibrotic pathways, driven by transforming growth factor-beta (TGF-β), are central to the development of tubulointerstitial fibrosis 9.
•Metabolic and Hemodynamic Factors: Hyperglycemia, hypertension, and dyslipidemia all contribute to the progression of CKD through various mechanisms, including oxidative stress, endothelial dysfunction, and the accumulation of advanced glycation end products.
Specialist Work-up: From Detection to Etiologic Diagnosis
A nephrology assessment should separate four tasks: confirming chronicity, classifying kidney function and albuminuria, identifying the cause, and estimating future risk. Repeat serum creatinine and urine ACR when transient changes are possible, review urine sediment directly when available, and document the timing and trajectory of prior results. CKD may be established by persistent albuminuria, urine-sediment abnormalities, persistent hematuria, tubular electrolyte abnormalities, histologic or structural abnormalities, a history of kidney transplantation, or eGFR <60 mL/min/1.73 m² for at least three months [1] [3].
Etiologic testing should be phenotype-directed. Active sediment, nephrotic-range proteinuria, rapid eGFR decline, systemic symptoms, or an unexplained rise in creatinine should prompt consideration of glomerular, vascular, interstitial, infectious, paraprotein-related, or genetic disease. Depending on the presentation, testing may include complement, ANA and anti-dsDNA, ANCA, anti-GBM, hepatitis B and C, HIV, monoclonal protein studies, PLA2R antibodies, renal imaging, or genetic testing. Testing should be interpreted in clinical context rather than as an indiscriminate panel.
When eGFR accuracy affects a major decision such as drug dosing, transplant evaluation, or treatment eligibility, consider a combined creatinine–cystatin C equation or measured GFR when feasible. Creatinine-based estimates are less reliable in non-steady-state conditions and at extremes of muscle mass, diet, body composition, or medication exposure [1] [3].
When to Consider Kidney Biopsy
Biopsy is most useful when the result is likely to change prognosis, treatment, or counseling. Common triggers include unexplained proteinuria, active urinary sediment, rapidly progressive kidney dysfunction, suspected immune-mediated disease, or an atypical course for presumed diabetic or hypertensive kidney disease. The report should integrate light microscopy, immunofluorescence, and electron microscopy, with clinicopathologic correlation and appropriate specimen triage.
The clinical presentation of CKD is often insidious, with most patients remaining asymptomatic until the advanced stages of the disease. Early detection relies on laboratory screening of at-risk individuals. As CKD progresses, a constellation of signs and symptoms, collectively known as uremia, may develop.
Laboratory Evaluation
The cornerstone of CKD diagnosis and monitoring is laboratory evaluation, which includes:
•Estimation of GFR: The 2021 CKD-EPI creatinine equation is the recommended method for estimating GFR in adults 2. Cystatin C-based equations are a useful alternative, particularly in patients with altered muscle mass.
•Assessment of Albuminuria: A spot urine ACR is the preferred method for quantifying albuminuria 2.
•Serum Chemistry: A comprehensive metabolic panel is essential for assessing electrolytes, acid-base status, and markers of bone and mineral metabolism.
•Hematologic Assessment: A complete blood count is necessary to screen for anemia, a common complication of CKD.
Imaging Studies
Renal ultrasonography is the most useful imaging modality in the initial evaluation of CKD. It provides information about kidney size, echogenicity, and the presence of hydronephrosis, cysts, or masses. Small, echogenic kidneys are characteristic of advanced CKD.
Renal Biopsy
A renal biopsy is indicated in patients with atypical presentations, rapidly progressive CKD, or when a specific diagnosis is needed to guide therapy. It remains the gold standard for diagnosing glomerular diseases and tubulointerstitial nephritis.
Quantitative Risk Assessment
The CGA framework is the starting point, not the endpoint, of prognostication. Interpret eGFR category together with ACR, underlying cause, rate of eGFR change, episodes of acute kidney injury, blood-pressure burden, and competing cardiovascular risk. A stable patient with low albuminuria may have a different prognosis from a patient with the same eGFR and rapidly increasing albuminuria.
The Kidney Failure Risk Equation (KFRE) can estimate 2-year and 5-year risk of kidney failure in appropriately validated populations and can support referral, modality education, access planning, and transplant evaluation. Use a regionally validated version when available, document the variables and date used, and avoid presenting a risk estimate as a substitute for clinical judgment. eGFR slope should be calculated from serial values over an adequate interval and interpreted cautiously after acute illness or medication-related hemodynamic changes.
| Risk signal | Why it matters | Practical response |
|---|---|---|
| Increasing ACR | Signals worsening glomerular injury and higher kidney and cardiovascular risk | Confirm persistence, review cause and therapy, and intensify risk reduction |
| Accelerated eGFR decline | May indicate active disease, AKI episodes, obstruction, nephrotoxins, or treatment-related change | Reassess chronology, medications, volume status, urine findings, and etiology |
| High KFRE risk | Supports proactive kidney-failure education and planning | Coordinate transplant evaluation, access or PD planning, and shared decision-making |
The staging of CKD, based on the GFR categories, provides a framework for management and prognosis. Each stage is associated with a different level of risk for progression to ESRD and other adverse outcomes.
•Stages G1-G2: Patients in these early stages have normal or mildly reduced GFR but have other evidence of kidney disease. Management focuses on treating the underlying cause and reducing cardiovascular risk.
•Stages G3a-G3b: These stages represent moderate CKD, and patients are at increased risk for complications such as anemia and mineral and bone disorders. Intensive management of risk factors is crucial to slow progression.
•Stage G4: This is severe CKD, and patients should be referred to a nephrologist for management of complications and preparation for renal replacement therapy.
G5 denotes kidney failure by eGFR category, but it does not mandate immediate dialysis. Dialysis initiation should be guided by symptoms, refractory electrolyte or acid–base abnormalities, uncontrolled volume or blood pressure, nutritional or functional decline, and the patient’s goals. Conservative kidney management is an appropriate option for selected patients after shared decision-making [1].
Prognosis in CKD is determined by the GFR, the degree of albuminuria, and the underlying cause of the disease. The KDIGO guidelines provide a heat map that combines GFR and albuminuria categories to stratify patients into low, moderate, high, and very high-risk groups for progression to ESRD.
Disease-Modifying Pharmacotherapy
Management should combine cause-specific therapy with therapies that reduce intraglomerular pressure, albuminuria, cardiovascular events, and kidney-failure risk. Treatment should be titrated with explicit monitoring plans rather than prescribed as isolated medication lists.
| Therapy | Specialist considerations | Monitoring and safety |
|---|---|---|
| ACE inhibitor or ARB | Use in appropriate albuminuric CKD and titrate to the highest tolerated dose; do not combine ACE inhibitor and ARB therapy. | Check creatinine and potassium after initiation or dose changes; address hyperkalemia rather than reflexively abandoning indicated therapy |
| SGLT2 inhibitor | Consider in eligible CKD with or without diabetes according to eGFR, albuminuria, and heart-failure context. | Explain the expected early hemodynamic eGFR dip, genital and volume-related adverse effects, sick-day and perioperative holding, and ketoacidosis warning symptoms |
| Finerenone | Consider in type 2 diabetes with CKD and persistent albuminuria despite optimized RAAS inhibition when potassium and eGFR criteria are satisfied | Check potassium at baseline and during follow-up; distinguish established diabetic-CKD evidence from emerging non-diabetic-CKD evidence [1] [3] |
| GLP-1 receptor agonist | Useful in appropriate patients with type 2 diabetes, obesity, and cardiovascular risk; integrate with the broader metabolic plan | Assess gastrointestinal effects, nutritional status, glycemic therapy interactions, and local regulatory indications; cite emerging guidance separately from finalized guidelines [2] |
Medication Stewardship and AKI Prevention
Every CKD review should include dose assessment using the best available kidney-function estimate, medication reconciliation, NSAID avoidance, contrast-risk assessment, and counseling about acute illness. “Sick-day” instructions should be individualized and should specify which medicines require temporary review rather than encouraging unsupervised medication cessation. The goal is to prevent AKI while preserving beneficial disease-modifying therapy [1] [3].
The management of CKD is tailored to the stage of the disease and is focused on slowing progression, preventing and treating complications, and preparing for renal replacement therapy when necessary.
Early-Stage CKD (G1-G3a)
The primary goals of management in early-stage CKD are to treat the underlying cause and to modify risk factors for progression. Key interventions include:
For many adults with CKD who are not receiving dialysis, KDIGO suggests a standardized office systolic blood-pressure target of <120 mmHg when tolerated. This target should not be applied to non-standardized clinic readings or treated as a universal diastolic target. Individualize therapy when orthostatic symptoms, frailty, falls, limited life expectancy, or treatment burden change the risk–benefit balance [1].
•RAAS Inhibition: ACE inhibitors or ARBs are the cornerstone of therapy for patients with albuminuria, as they have been shown to reduce proteinuria and slow the rate of GFR decline 8.
•SGLT2 Inhibition: SGLT2 inhibitors have emerged as a new standard of care for patients with CKD, with and without diabetes, due to their proven benefits in reducing the risk of CKD progression and cardiovascular events 10.
•Glycemic Control: In patients with diabetes, optimal glycemic control is essential to prevent the progression of diabetic nephropathy.
•Lifestyle Modifications: Dietary sodium restriction, weight management, and smoking cessation are important adjunctive therapies.
Late-Stage CKD (G3b-G5)
As CKD progresses, management becomes more complex and focuses on the treatment of complications and preparation for renal replacement therapy. In addition to the interventions for early-stage CKD, management of late-stage CKD includes:
•Anemia Management: Treatment with iron supplementation and erythropoiesis-stimulating agents (ESAs) is often necessary to correct anemia.
•Mineral and Bone Disorder Management: This involves the use of phosphate binders, vitamin D analogs, and calcimimetics to control secondary hyperparathyroidism.
•Metabolic Acidosis Correction: Oral alkali therapy is used to maintain a normal serum bicarbonate level.
Dietary therapy should be individualized rather than reflexively restrictive. Emphasize sodium reduction, adequate—not excessive—protein intake, preservation of nutritional status, and potassium or phosphorus modification according to laboratory trends, dietary sources, symptoms, and treatment goals. Referral to a renal dietitian is particularly valuable in G4–G5 CKD.
•Preparation for Renal Replacement Therapy: This includes education about the different modalities of dialysis and transplantation, as well as the timely creation of a vascular access for hemodialysis.
7. Managing the Complications of CKD
CKD is a systemic disease that is associated with a wide range of complications that contribute to its high morbidity and mortality.
Cardiovascular Disease
Cardiovascular disease is the leading cause of death in patients with CKD 11. The risk of cardiovascular events is increased even in the early stages of CKD and rises exponentially as GFR declines. The pathophysiology of cardiovascular disease in CKD is multifactorial and involves both traditional risk factors (hypertension, dyslipidemia, diabetes) and non-traditional, uremia-related risk factors (inflammation, oxidative stress, vascular calcification).
Anemia
Anemia is a common complication of CKD, primarily due to decreased production of erythropoietin by the failing kidneys. It is associated with fatigue, reduced quality of life, and an increased risk of cardiovascular events.
Mineral and Bone Disorders
CKD-mineral and bone disorder (CKD-MBD) is a systemic disorder characterized by abnormalities in mineral and bone metabolism and extraskeletal calcification. It is a major cause of morbidity in patients with CKD, leading to bone pain, fractures, and vascular calcification.
Timing and Modality Planning
Kidney-failure planning should begin before urgent dialysis is required. Discuss transplant referral, living-donor evaluation, home therapies, in-center hemodialysis, peritoneal dialysis, vascular-access or catheter planning, conservative kidney management, and palliative-care support according to prognosis, symptoms, functional status, social circumstances, and patient preferences.
Dialysis initiation should not be triggered by eGFR alone. Consider initiation when symptoms or signs attributable to kidney failure are refractory to medical therapy, including persistent hyperkalemia or acidosis, uncontrolled volume overload or blood pressure, progressive nutritional deterioration, uremic pericarditis, encephalopathy, or clinically significant decline in function. The decision should be shared with the patient and revisited as the clinical trajectory changes [1].
Transplant and Conservative Kidney Management
For suitable candidates, preemptive transplantation and living-donor evaluation should be considered before dialysis. Transplant assessment should include cardiovascular evaluation, infection screening, malignancy screening, sensitization and HLA considerations, psychosocial assessment, and medication planning. Conservative kidney management is active care focused on symptom control, advance-care planning, psychosocial support, and treatment aligned with the patient’s goals; it is not abandonment of care.
When CKD progresses to ESRD (Stage G5), renal replacement therapy is required to sustain life. The main modalities of renal replacement therapy are dialysis and kidney transplantation.
Dialysis
Dialysis is a process that removes waste products and excess fluid from the blood when the kidneys are no longer able to do so. The two main types of dialysis are:
•Hemodialysis: In hemodialysis, blood is circulated outside the body and through a machine with a special filter that removes wastes and excess fluid. Hemodialysis is typically performed three times a week for 3-4 hours at a dialysis center.
•Peritoneal Dialysis: In peritoneal dialysis, a cleansing fluid is circulated through a catheter into the peritoneal cavity. The peritoneal membrane acts as a natural filter to remove wastes and excess fluid. Peritoneal dialysis is a home-based therapy that can be performed either manually throughout the day or automatically by a machine at night.
Kidney Transplantation
Kidney transplantation is the treatment of choice for most patients with ESRD. It offers the best long-term survival and quality of life. However, the availability of donor kidneys is limited, and patients must take lifelong immunosuppressive medications to prevent rejection of the transplanted kidney.
9. Summary and Clinical Pearls
•CKD is a common and serious condition that requires a systematic approach to diagnosis and management.
•The KDIGO CGA classification system is an invaluable tool for staging, risk stratification, and guiding therapy.
•The cornerstones of CKD management are blood pressure control, RAAS inhibition, and SGLT2 inhibition.
•A multidisciplinary approach, involving nephrologists, dietitians, nurses, and social workers, is essential for optimal patient outcomes.
•Early detection and intervention are key to slowing the progression of CKD and reducing its associated complications.
10. References
[1] Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-180.
[3] Vaidya SR, Aeddula NR. Chronic Kidney Disease. In: StatPearls. StatPearls Publishing; 2024.
[15] Awdishu L, et al. KDIGO 2024 CKD guideline primer. Am J Health-Syst Pharm. 2025;82:660–671. Full text.
[14] Levin A, et al. Executive summary of the KDIGO 2024 CKD guideline. Kidney Int. 2024;105:684–701. PubMed.
[13] KDIGO 2017 Clinical Practice Guideline Update for CKD–Mineral and Bone Disorder. KDIGO guideline resources.
[12] KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease. KDIGO guideline resources.
Question 1
According to KDIGO guidelines, Chronic Kidney Disease (CKD) is defined as kidney abnormalities present for a duration greater than:
A) 1 month
B) 3 months
C) 6 months
D) 12 months
Answer: B) 3 months
Explanation: CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health.
Question 2
Which GFR category represents kidney failure (ESRD) and typically requires renal replacement therapy?
A) G2
B) G3b
C) G4
D) G5
Answer: D) G5
Explanation: GFR category G5 is defined as GFR <15 mL/min/1.73 m², which corresponds to kidney failure or ESRD.
Question 3
Which of the following is the leading cause of death in patients with Chronic Kidney Disease?
A) Infection
B) Cardiovascular disease
C) Malnutrition
D) Cancer
Answer: B) Cardiovascular disease
Explanation: Cardiovascular disease is the leading cause of morbidity and mortality in patients with CKD, even in early stages.
Question 4
Which class of medications is considered first-line for blood pressure control and proteinuria reduction in CKD patients, especially those with albuminuria? A) Beta-blockers B) Calcium channel blockers C) ACE inhibitors or ARBs D) Diuretics
Answer: C) ACE inhibitors or ARBs Explanation: ACE inhibitors and ARBs are renoprotective and are recommended as first-line agents for blood pressure control and proteinuria reduction in CKD patients with albuminuria.
Question 5
Which of the following is a common complication of CKD due to decreased erythropoietin production by the kidneys?
A) Hypercalcemia
B) Anemia
C) Hypoglycemia
D) Leukocytosis
Answer: B) Anemia
Explanation: Anemia is a common and significant complication of CKD, primarily due to the kidneys’ reduced ability to produce erythropoietin.
Question 6
Which of the following is considered the gold standard treatment for End-Stage Renal Disease (ESRD) offering the best quality of life and survival?
A) Hemodialysis
B) Peritoneal Dialysis
C) Kidney Transplantation
D) Conservative management
Answer: C) Kidney Transplantation
Explanation: Kidney transplantation is generally considered the optimal treatment for ESRD, providing superior quality of life and survival compared to dialysis.
Question 7
Which of the following is a key pathophysiological mechanism contributing to the progression of CKD, regardless of the initial cause?
A) Increased renal blood flow
B) Glomerular hypertrophy and hyperfiltration
C) Decreased RAAS activation
D) Reduced inflammation
Answer: B) Glomerular hypertrophy and hyperfiltration
Explanation: Compensatory hypertrophy and hyperfiltration in remaining nephrons initially maintain GFR but eventually lead to further injury and progression of CKD.
Question 8
Which of the following is a component of CKD-Mineral and Bone Disorder (CKD-MBD)?
A) Hypernatremia
B) Hypophosphatemia
C) Renal osteodystrophy
D) Hypermagnesemia
Answer: C) Renal osteodystrophy
Explanation: Renal osteodystrophy, a type of bone disease, is a key component of CKD-MBD, resulting from disturbances in mineral and hormone metabolism.
Question 9
For a patient with ESRD, which type of vascular access is preferred for hemodialysis due to lower infection and thrombosis rates?
A) Central venous catheter
B) Arteriovenous graft (AVG)
C) Arteriovenous fistula (AVF)
D) Peritoneal catheter
Answer: C) Arteriovenous fistula (AVF)
An AV fistula may offer durable access for selected patients, but access choice should follow an individualized life-plan that considers vessel anatomy, anticipated dialysis duration, urgency, age, comorbidity, prior access, and patient preference. A graft or catheter may be appropriate in specific circumstances.
Question 10
Which of the following dietary modifications is generally recommended for patients with advanced CKD? A) High sodium intake
B) High protein intake
C) Low phosphate intake
D) Unlimited fluid intake
Answer: C) Low phosphate intake
Explanation: Dietary phosphate restriction is crucial in advanced CKD to manage hyperphosphatemia and prevent CKD-MBD complications.